A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy delandistrogene moxeparvovec (Elevidys), Sarepta Therapeutics said in a statement ...
Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy treatment. The patient was a young man who suffered acute liver failure ...
Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 ...
8don MSN
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.
WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting more than 25%.
Clinical Trials Arena on MSN6d
Epicrispr secures $68m for facioscapulohumeral muscular dystrophy therapy trialEpicrispr Biotechnologies has raised $68m in the initial close of its Series B financing round to commence the clinical trial ...
New Gene Therapy Approach Shows Promise for Duchenne Muscular Dystrophy July 24, 2024 — Researchers have made a significant breakthrough in developing a new gene therapy approach that restores ...
2021;6(11):887-896. [2] AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). Available at: https ...
WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback